Sense Proteomic Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sense Proteomic Ltd.
Astex Cashes in with metaGen
Astex Technology's takeover of Schering AG spin-out metaGen Pharmaceuticals provides the Cambridge-based firm with more cash, a stronger relationship with a pharmaceutical partner, complementary technology assets, and, potentially, an improved preclinical pipeline. MetaGen investors inch closer to an exit by trading stakes in an early-stage, unfloatable company for a piece of a more mature, well-funded firm several steps closer to an IPO.
Aliga: Are Mergers Between Biology and Chemistry Financeable?
The combination of Dutch firm Kiadis and Germany's Biofrontera, a technological fit, now needs to score with investors and provide the proposed new firm with enough cash to survive the biotech drought.
M&A Makes Sense for Procognia
Procognia's acquisition of fellow Apax portfolio company Sense Proteomic could indicate a more proactive stance from VCs intent on consolidating their bets behind likely winners.
Recent Dealmaking (02/2003)
Summarizing the month in European dealmaking.
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.